Positively Positive - Living with HIV/AIDS:
HIV/AIDS News
HIV and AIDS News from around the world
Worldwide 88.4 million people have been infected with HIV.
Worldwide 42.3 million people with HIV have died.
Practicing Safe Sex is our best resource in preventing HIV infection through sexual contact.
Sexual contact accounts for 95 percent of all new HIV infections worldwide.
Safe Sex = Disease Prevention – STAY SAFE!
Use A Condom Every Time!
“HIV needs to be in the media each and every day as most people only see snippets of news and these are not effective enough. For this reason, in 2007, I decided to include an HIV/AIDS News page where people could find information on many HIV (Human Immunodeficiency Virus) and AIDS (Acquired Immune Deficiency Syndrome) related issues, Infectious Disease,
and more.
I collaborate with individuals, groups, and organizations throughout the world, to include their HIV/AIDS news articles, press releases, events, workshops, conferences, and more on PositivelyPositive.ca. News items stay on the HIV/AIDS News page for a month,
and then News items go into the HIV/AIDS News Archives.”
Bradford McIntyre
Life expectancy of women with HIV in B.C. hasn't increased as much as men's: new research
May 31, 2025 - by Michelle Gomez - CBC News - British Columbians with HIV are living much longer now than a few decades ago, but less so for women than men
While British Columbians living with HIV are living much longer than a few decades ago, the life expectancy for women isn't increasing at the same rate as men's, according to a recent study by the B.C. Centre for Excellence in HIV/AIDS.
Data gathered between 1996 to 2001 and 2012 to 2020 shows that in B.C., men's life expectancy rose from 44 to 68 years old, while the life expectancy for women only rose from 42 to 61 years old.
Read more...
HIV’s Most Promising Breakthrough Has Taken a Hit
MAY 31, 2025 - By Katherine J. Wu - The Atlantic - Several mRNA vaccine trials found a debilitating side effect, and now the Trump administration is cutting funding for more research.
Solving HIV vaccination—a puzzle that scientists have been tackling for decades without success—could be like cracking the code to a safe. The key, they now think, may be delivering a series of different shots in a specific sequence, iteratively training the body to produce a strong, broad immune response that will endure against the fast-mutating virus, ideally for a lifetime.
Read more...
‘Infected blood gave me HIV as a baby but I still can’t get compensation I deserve’
MAY 31, 2025 - By Rebecca Thomas - The Independent - Exclusive: Infected Blood Scandal victims with HIV feel they are having to ‘prove their worth’
Solving HIV vaccination—a puzzle that scientists have been tackling for decades without success—could be like cracking the code to a safe. The key, they now think, may be delivering a series of different shots in a specific sequence, iteratively training the body to produce a strong, broad immune response that will endure against the fast-mutating virus, ideally for a lifetime.
Read more...
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
May 30 (Reuters) - By Julie Steenhuysen and Deena Beasley - Reuters - Exclusive: Infected Blood Scandal victims with HIV feel they are having to ‘prove their worth’
Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump Administration’s pullback in aid spending.
Some AIDS experts, including activists and doctors, say the Gilead drug, lenacapavir, could help end the 44-year-old epidemic that infects 1.3 million people a year and is estimated by the World Health Organization to have killed more than 42 million.
Read more...
PrEP Use Among Young Adults Increased Eightfold in Last Decade
May 29, 2025 - By Laura Schmidt - POZ - But barriers remain, and PrEP use could be further boosted. Plus: States with greater PrEP uptake see greater drops in HIV cases.
Young adults in the United States are taking PrEP to prevent HIV at a rate eight times higher than a decade ago, according to a study by University of Michigan Medical School (UM) researchers, who note, however, that more can be done to promote and boost access to PrEP.
Pre-exposure prophylaxis (PrEP) refers to daily pills or long-lasting injectables that are highly effective at preventing HIV. People at risk of exposure to HIV can take PrEP. In contrast, post-exposure prophylaxis (PEP), a prescription of daily HIV meds usually taken for about a month, is prescribed after a potential exposure. PEP must be started within 72 hours after the exposure.
Read more...
Researchers Take Next Steps Toward an HIV Vaccine
May 28, 2025 - By Liz Highleyman - POZ - Novel vaccine approaches are making progress, but it will likely be years before large trials show whether they can prevent HIV.
HIV vaccine approaches that aim to train the immune system to produce specialized antibodies against the virus have taken the next steps forward, two research teams reported in Science to coincide with HIV Vaccine Awareness Day on May 18.
Both studies showed that different engineered immunogens could trigger production of precursor immune cells with the potential to produce broadly neutralizing antibodies (bnAbs) that work against diverse strains of HIV. One study enrolled participants in Africa, which bears the brunt of the epidemic.
Read more...
In a New Era of Fear for the HIV Community, Our Unity Is Our Strength
May 28, 2025 - By Sean Leviashvili - TheBody - Like so many in the LGBT+ community, I grew up in a constant state of fear. There was the fear of rejection, the fear of isolation, and because I was also born with cerebral palsy, the fear of being bullied. But no fear was as pervasive, as all-consuming, as the fear of HIV and AIDS.
Read more...
HIV Discovery Could Open Door to Long-Sought Cure
May 28, 2025 - UVA Health Newsroom - School of Medicine scientists have uncovered a key reason why HIV remains so difficult to cure: Their research shows that small changes in the virus affect how quickly or slowly it replicates, and how easily or stubbornly it can reawaken from hiding. These insights bring researchers closer to finding ways to flush out the dormant virus and eliminate it for good.
Thanks to remarkable progress in HIV treatment, the virus can often be suppressed to undetectable levels in the blood, eliminating most disease symptoms, and preventing transmission to others. But HIV never truly goes away. Instead, it hides in the body in a dormant, or “latent,” state, and if medications are ever stopped it can reemerge. In this stealth mode, the virus evades both antiretroviral drugs and the immune system, posing one of the biggest challenges to finding a cure.
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. - Event: NanoViricides Presentation at the BIO International Convention, 2025, Boston, MA
Day & Date: Monday, June 16, 2025
Time: 2:30 pm
Location: Room 153B, Boston Convention and Exhibition Center
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Monday, June 16th, at 2:30pm at the BIO International Convention 2025 in Boston, MA.
In a New Era of Fear for the HIV Community, Our Unity Is Our Strength
May 27, 2025 - By Donald Padgett - The Advocate - This will be the final year for the seven-day AIDS/LifeCycle fundraising ride from San Francisco to Los Angeles. Schiff previously participated when he served in the U.S. House of Representatives.
Democratic U.S. Sen. Adam Schiff will participate in the upcoming AIDS/LifeCycle 2025 ride in California, making him the first U.S. senator to take part in the seven-day fundraising bike ride from San Francisco to Los Angeles.
Organizers of the annual ride, which first started in 2002, earlier announced that 2025 would be the final year of the fundraiser due to rising costs and declining participation.
Read more...
ViiV HEALTHCARE POSITIVE PERSPECTIVES 3 STUDY FINDS WIDESPREAD COMMUNICATION BARRIERS: HALF OF PEOPLE LIVING WITH HIV FEEL UNHEARD BY HEALTHCARE PROVIDERS DESPITE HIGH TRUST
London, 27 May 2025 – ViiV Healthcare - - Early data from Positive Perspectives 3, an international survey of people living with HIV, shows nearly 40% did not make joint treatment decisions with their provider -
- Data also indicate that despite high awareness, there is lack of understanding and belief in “Undetectable = Untransmittable” -
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced interim data from the third wave of the global Positive Perspectives (PP3) study of people living with HIV. Initial results show that while a high proportion of individuals trust their healthcare provider (HCP), a communications gap exists. Many indicated that they sometimes feel unheard by their HCP, and did not make decisions together about their current antiretroviral (ART) regimen. Those who were satisfied with their ART regimen were less likely to intentionally skip doses and more likely to report good overall health outcomes.
Stay safe this summer: protect yourself from STIs in the upcoming holiday season
Stockholm, 27 May 2025 - European Centre for Disease Prevention and Control (ECDC) - Sexually transmitted infections (STIs) are spreading across Europe, and the European Centre for Disease Prevention and Control (ECDC) is urging everyone to stay informed and practice safer sex during upcoming holidays, festivals, and travel this summer season.
With increased social interaction and sexual encounters during the summer, there is an increased possibility of STIs spreading. This underscores the importance of understanding risks, knowing one’s health status, and making informed decisions about sexual health, as the most recent EU/EEA level data show that STIs are still increasing in many parts of the region.
ECDC emphasises the importance of safer sex practices, including consistent condom use for vaginal, anal, and oral sex. Getting tested for STIs is recommended before having sex without a condom with new partners, as people can have an STI without having any symptoms. If that is not possible, it is important to get tested after having sex without a condom.
Targeting the Integrator complex improves reactivation of HIV
May 26, 2025 - By H Lewis - Fred Hutchinson Cancer Center - From the Emerman Lab, Human Biology Division
It is not an exaggeration to say that the development of antiretroviral therapy is one of the most significant accomplishments in the history of medicine. In the early days of the HIV pandemic, newly diagnosed people measured time in months; now, the the expected lifespan for people living with HIV has lengthened into years and decades. Antiretroviral therapy (ART) has saved millions of lives, and it took decades of research by many interdisciplinary teams to make this happen.
Despite this monumental success, there is still no cure. ART lowers viral burden, but it cannot clear the HIV reservoir—the pool of long-lived infected cells where HIV hides—which can not only persist but expand even in the presence of ART. As a result, people living with HIV have to take their medicine every day for the rest of their lives or risk viral rebound.
This is because there is currently no way to remove virus from infected cells and latent HIV is never truly silent. The viral genome, which is integrated into the host DNA in a form called the provirus, periodically reactivates in small “blips” triggered by events such as an immune response to another infection. Without ART, reactivated HIV infects and destroys the very cells that are needed to control HIV infection, leading to swift disease progression. With ART, these blips are quickly shut down, stopping the virus in its tracks and allowing the people living with HIV to live a long and healthy life.
Portable HIV Monitoring Device Shows Promise for Remote Settings
Newswise - 26-May-2025, by Chinese Academy of Sciences - Accurate monitoring of CD4+ T cell counts is vital for evaluating immune health and guiding treatment in people living with Human Immunodeficiency Virus (HIV). Yet conventional tools like flow cytometry, while highly effective, are expensive, complex, and ill-suited for widespread use in remote or resource-limited areas. Many portable alternatives remain constrained by low sensitivity, intricate sample handling, or high operational costs. Optical and fluorescence-based systems, though advanced, further compound these issues with their maintenance and equipment needs. Due to these limitations, there is an urgent need for cost-effective, standalone diagnostic platforms that can be deployed directly at the point of care to ensure timely HIV monitoring.
In a collaborative effort, researchers from the University of Bath and Nanyang Technological University have developed an integrated microfluidic electrochemical biosensor for detecting CD4+ T cells. Their findings (DOI: 10.1038/s41378-025-00893-8), published on April 9, 2025, in Microsystems & Nanoengineering, showcase a polydimethylsiloxane (PDMS)-based chip with gold electrodes that uses impedance-based, label-free sensing. Tailored for low-resource settings, the device enables minimizing handling steps and simplifying sample processing, and delivers results within clinically relevant thresholds. This breakthrough marks an important advance toward enabling real-time HIV diagnostics outside of conventional laboratories.
Haiti running out of HIV medication due to USAID funding cuts
MAY 25, 2025- africanews - Haiti running out of HIV medication due to USAID funding cuts.
More than 150,000 people in Haiti have HIV or AIDS, although the number is believed to be much higher.
A Black Queer Kentuckian’s Thoughts on HIV/AIDS Stigma and History
May 24, 2025 - by Kevin Garner - Queer Kentucky - As a Black, gay, queer man, I understand firsthand the deep and often painful intersection of identity, community, and health when it comes to the history of AIDS and HIV. For far too long, the story of AIDS has been framed in ways that ignore or marginalize the experiences of people like me—Black and queer individuals—who have been disproportionately impacted by this epidemic. Knowing the history of AIDS and HIV within our communities is crucial, not only to understand how we’ve survived, but to honor the lives and legacies of those we’ve lost along the way.
The HIV/AIDS crisis didn’t just ravage communities—it reshaped our cultural landscape, leaving lasting effects on families, relationships, and even how we view health and care within our communities. For Black people, the impact has been multifaceted, compounded by systemic racism, stigma, and a long history of exclusion from vital healthcare resources. The stories of Black lives lost, the strength of our collective resistance, and the ongoing fight for equity are narratives that too often go untold or overlooked.
Over $17 Million Raised at 31st Edition of amfAR Gala Cannes
Antibes, France - May 23, 2025 - amfAR, The Foundation for AIDS Research - Taraji P. Henson Hosted
Duran Duran, Ciara, and Adam Lambert Performed
Presented by Chopard
Over $17 million was raised last night for amfAR’s AIDS research programs at the 31st edition of amfAR Gala Cannes. The black-tie gala, which took place at the Hôtel du Cap-Eden-Roc, was hosted by Academy Award-nominated actor, producer, and advocate Taraji P. Henson and featured captivating performances by iconic GRAMMY® Award-winning rock band Duran Duran, GRAMMY® Award-winning singer/songwriter, entrepreneur, and philanthropist Ciara, and GRAMMY®-nominated chart-topping superstar entertainer and current frontman of Queen Adam Lambert. The evening also included a dinner, a live auction of one-of-a kind luxury items and contemporary art, and a fashion show curated by Carine Roitfeld.
HIV progress at risk: Haitians join global call over halted US aid
May 23, 2025 - by Juhakenson Blaise -The Haitian Times - Protesters in Port-au-Prince echo a growing transnational alarm over USAID’s halted funding for antiretroviral drugs, warning of setbacks in HIV prevention and erosion of progress made in recent years.
In early July 1981, Barry Deeprose stopped to read a New York Times article pinned to a bulletin board at the Gays of Ottawa centre, where he volunteered as a peer counsellor.
The article described a rare and often rapidly fatal form of cancer diagnosed in 41 homosexual men, mostly in New York City and San Francisco.
Read more...
Trump cuts will cause a spike in HIV cases in L.A. and across the country, warn Democrats and public health advocates
May 23, 2025 -By Kevin Rector and Susanne Rust - Los Angeles Times - A growing coalition of HIV prevention organizations, health experts and Democrats in Congress are sounding the alarm over sweeping Trump administration cuts to HIV/AIDS prevention and surveillance programs nationally, warning they will reverse years of progress combating the disease and cause spikes in new cases — especially in California and among the LGBTQ+ community.
Read more...
Maryland Repeals Outdated HIV Crime Law
May 23, 2025 - By Trent Straube - POZ - Maryland is the fifth state to repeal unjust laws that criminalize people with HIV. Such laws often target minority populations, including Black men.
Finally, some good news this week about lawmakers. The governor of Maryland, Wes Moore, signed into law a bill that decriminalizes HIV. Specifically, the bill repeals an old law that made it a crime to “knowingly transfer or attempt to transfer” HIV to another individual. Under outdated laws like this, people with HIV can be sentenced to prison in cases where HIV was not transmitted and their only crime was allegedly not disclosing their status. Such unjust laws not only lead to stigma but also to folks not getting tested to learn their HIV status.
Read more...
The harrowing human rights battle of Barry Deeprose
May 23, 2025 - By Andrew Duffy - Ottawa Citizen - Forty years ago, Deeprose launched the AIDS Committee of Ottawa, a volunteer organization with a shoestring budget and an enormous task.
In early July 1981, Barry Deeprose stopped to read a New York Times article pinned to a bulletin board at the Gays of Ottawa centre, where he volunteered as a peer counsellor.
The article described a rare and often rapidly fatal form of cancer diagnosed in 41 homosexual men, mostly in New York City and San Francisco.
Read more...
Extreme weather events linked to HIV vulnerabilities among sex workers and sexually diverse men in Kenya
Toronto, ON - 22-May-2025 - University of Toronto, Factor-Inwentash Faculty of Social Work - Researchers find interconnections between climate change-related extreme weather events and HIV vulnerabilities, such as increased transactional sex, reduced condom agency, increased risk of sexual violence, and LGBTQ stigma
New research published earlier this month in AIDS and Behavior highlights links between extreme weather events, such as drought and flooding, and increased HIV vulnerabilities among sex workers and sexually diverse men in Nairobi, Kenya.
While there has been growing attention to the impacts of climate change on HIV vulnerabilities, past research has largely overlooked key populations, such as sex workers and gay, bisexual, and other men who have sex with men (gbMSM), comprising a critical knowledge gap.
“Climate shocks and extreme weather events are already known to exacerbate poverty and resource scarcity, which can amplify HIV risk. Sex workers and gbMSM may be particularly vulnerable to these adversities because of the compounding impacts of stigma and social marginalization,” says lead author Carmen Logie, a Professor at the University of Toronto’s Factor-Inwentash Faculty of Social Work (FIFSW) and an Adjunct Professor at the United Nations University Institute for Water, Environment, and Health.
KULeuven researchers publish HIV virus disabling breakthrough
22 May 2025 - By Alexandra Walsh - The Brussels Times - KULeuven researchers led by Professor of the faculty of Medicine Zeger Debyser have discovered an approach to make the HIV virus permanently harmless.
Published in the scientific journal 'Nature Communications,' the research presents a new way to disable the virus in cells within a controlled factory environment.
According to the World Health Organisation currently just under 40 million people were living with HIV at the end of 2023, with over 600,000 related deaths in the same year.
Read more...
Few people with HIV in England starting statins despite new recommendations
22 May 2025 - By Gus Cairns - aidsmap - GPs could take a more active role in suggesting them
Six poster presentations at last month’s British HIV Association (BHIVA) Conference in Brighton found that only a minority of people with HIV are being offered and starting to take the cholesterol-lowering statin drugs. This is despite a November 2023 recommendation by BHIVA that “All people living with HIV aged 40 years or older should be offered a statin for primary prevention of cardiovascular disease”.
Several barriers to obtaining statins were identified. A surprisingly low proportion of HIV doctors had discussed statins with their patients; clinics were still, in the main, using CVD risk scores to prioritise who over 40 should get them; and some people were turning them down due to fear of side effects.
Read more...
Cannabis Use Disorder Is Increasing, Especially Among Older Adults and People Living With HIV
March 21, 2021 - By Jillian McKoy - Boston University School of Public Health - A new study underscores the need for universal screening and treatment for the disorder, as well as concerted research to better understand the benefits and risks of cannabis among different populations.
Adults ages 65 and older are the fastest-growing age group to use cannabis in the United States. Cannabis use is particularly high among people living with HIV, an aging population that has reported taking this drug to manage HIV-related symptoms, side effects from antiretroviral therapy, pain, and moods.
This growing use of cannabis has contributed to an increase in cannabis use disorder (CUD) in the US over the last 20 years, according to a new study led by a School of Public Health researcher.
Published in the Journal of Addiction Medicine, the study found that CUD diagnoses rose substantially across all age, race/ethnicity, and comorbidity subgroups nationwide from 2000 to 2022. These diagnoses were consistently higher among people living with HIV, compared to people living without HIV, and people over 65 experienced the greatest relative increase.
‘My greatest fear is that we will return to the dark days of the epidemic’
May 21, 2025 - UNAIDS - UNAIDS Country Director reports on the impact of funding cuts to the HIV response
The HIV response in Zambia, known as a model of success in sub-Saharan Africa, is now facing major challenges following the abrupt and significant cuts to US funding. It has led to widespread disruption: clinics have closed, prevention services have been scaled back, and thousands have lost access to lifesaving medication. Yet the Zambian government and partners are stepping in to protect the progress made.
In this interview, UNAIDS Country Director for Zambia, Isaac Ahemesah, details the fallout from these funding decisions on health services, vulnerable communities, and the country’s ability to sustain progress against HIV-and outlines what is urgently needed to avert further health crisis.
Read more...
UNAIDS encouraged by comments from Elon Musk that he will fix the US funding crisis for HIV services
GENEVA, 21 May 2025 - UNAIDS - Mr Musk made the remarks during an interview with Bloomberg’s Mishal Husain at the Qatar Economic Forum on 20 May
UNAIDS is deeply encouraged by the statement from Elon Musk that he will fix the current crisis related to a lack of US Government funding for lifesaving HIV services. UNAIDS is tracking daily the impacts of US funding cuts on HIV services for people living with and affected by HIV around the world as the data and stories of impact on UNAIDS website show.
Currently, many HIV prevention programs supported by the US President's Emergency Plan for AIDS Relief (PEPFAR) have been stalled. The Administration issued a limited waiver providing for continuity of some services, including comprehensive HIV testing and treatment, but it is not being fully implemented within countries, and the waiver excludes almost all HIV prevention services except those for pregnant and breastfeeding women.
HIV self-testing kit research with cisgender women in Canada
May 20, 2025 - CATIE NEWS - Canadian AIDS Treatment Information Exchange (CATIE) - An Ontario study looked at differences in HIV self-testing between cisgender women and men
Test positivity rates were similar, but cisgender women were less likely to report their results
Cis women reported lower uptake of testing for HIV than other sexually transmitted infections
HIV testing is an important step to better health. A person with a positive HIV test can get connected to care and treatment. HIV treatment today is highly effective and safe, and it can be taken as simply as one pill daily or as an injection once every two months.
A person with a negative HIV test can have a discussion with a healthcare provider about options for staying negative, including HIV pre-exposure prophylaxis (PrEP). Such options can include a daily pill or an injection once every two months.
Self-testing could be one way to bring more cisgender women into care, whether it’s for HIV treatment or to facilitate access to PrEP.
Hepatitis A and E: Underappreciated public health threats
May 20, 2025 - By Monica Stonehill & By Caitlyn Stulpin - Healio - Currently, more than 300 million people are diagnosed with hepatitis around the world, according to the World Hepatitis Alliance. Cases continue to rise, with more than 2 million new cases each year.
Among the five hepatitis viruses, hepatitis B, hepatitis C and hepatitis D usually cause chronic disease, liver cancer and cirrhosis, whereas hepatitis A and hepatitis E cause acute disease but may lead to more serious complications in certain populations, including pregnant people.
Read more...
Cutting HIV aid means undercutting US foreign and economic interests - Nigeria shows the human costs
May 19, 2025 - The Conversation - A little over two decades ago, addressing Nigeria’s HIV crisis topped U.S. President George W. Bush’s priorities. Africa’s most populous nation had 3.5 million HIV cases, and the disease threatened to destabilize the region and ultimately compromise U.S. interests. These interests included securing access to Nigeria’s substantial oil reserves, maintaining regional military stability and protecting trade partnerships worth billions.
Following years of agitation from AIDS activists, Bush launched the President’s Emergency Plan for AIDS Relief, or PEPFAR, in 2003. This U.S.-led HIV treatment program has since saved tens of millions of lives around the globe.
While living in Nigeria for my work as a medical anthropologist, I witnessed PEPFAR’s rollout and saw firsthand how the powerful therapies it provided transformed Nigerian lives. The women I worked with told me they could finally put aside the fears of death or abandonment that had consumed their days. Instead, they could focus on a newly expanded horizon of possibilities: building careers, finding love, having healthy children.
Now, however, a serious threat to preventing and treating HIV worldwide looms. The Trump administration’s decision to substantially restrict access to a vital HIV prevention tool – PEPFAR-funded preexposure prophylaxis, or PrEP – would cut off ongoing treatment for millions of people and block future access for countless others who need this protection..
UNAIDS calls on leaders at At the 78th World Health Assembly, UNAIDS calls for urgent action to avert millions of preventable HIV Infections and AIDS-related deaths
GENEVA, 19 May 2025 - UNAIDS - As funding cuts threaten to cause an additional 6 million new HIV infections and 4 million preventable AIDS-related deaths, UNAIDS is calling on governments and partners attending the 78th World Health Assembly (WHA) to recommit to ending AIDS by 2030.
UNAIDS estimates that an additional 2300 people are contracting HIV every day. Without immediate action to dismantle barriers to healthcare, strengthen community-led responses, and unlock sustainable financing, a catastrophic loss of life and millions more new HIV infections could reverse decades of progress.
Britta Will, Ph.D., named director of Gottesman Institute for Stem Cell Research and Regenerative Medicine at Albert Einstein College of Medicine
MAY 16, 2025 - (BRONX, NY) - Albert Einstein College of Medicine - Albert Einstein College of Medicine has appointed Britta Will, Ph.D., associate professor of oncology, of medicine and of cell biology, and the Diane and Arthur B. Belfer Scholar in Cancer Research, as the permanent director of the Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine.
Schulich researcher tackles HIV with machine learning
May 16, 2025 - By Cam Buchan - Western News - Western University - Abayomi Olabode uses data science, network analysis tools to battle the disease
Hiding behind numerous disguises, HIV has been evading researchers for years, leaving the search for a vaccine as elusive as the virus itself.
Once believed to exist as pure strains or subtypes, new research shows the virus evolves constantly, combining dangerous elements that complicate treatment.
As part of its evasive techniques, the virus can lie dormant in cells, avoiding treatments and the body’s own immune system. Meanwhile, the virus continues to exact a heavy global toll. The World Health Organization (WHO) estimates that, as of 2023, approximately 40-million people globally are living with HIV, 65 per cent of them in the WHO’s African Region.
HIV programmes will not collapse after Trump funding cuts, Motsoaledi says
May 16, 2025 -By Aarti Bhana - Mail&Guardian - Health Minister Aaron Motsoaledi says South Africa’s HIV/Aids programmes will not collapse despite the withdrawal of funding by the US, insisting that there are existing facilities which can absorb the affected patients.
Read more...
Cambodia showcases huge progress towards ending AIDS, announces a financial contribution to UNAIDS
PHNOM PENH, 16 May 2025 - UNAIDS - UNAIDS Executive Director, Winnie Byanyima, saw firsthand Cambodia’s strong progress towards ending AIDS as a public health threat during her 12-16 May mission. Among other achievements, the country treats 100% of people who are aware of their HIV status. Key approaches include national roll-out of modern HIV prevention and treatment tools, community-led service delivery and social protection. During the visit she discussed the sustainability of the response with the Royal Government and partners.
“Cambodia’s HIV response demonstrates that ending AIDS is possible for low- and middle-income countries when we combine political will, community leadership and international support,” Ms Byanyima said.
Meet the woman who has participated in every AIDS Walk New York
May 16, 2025 - CBS New York - Sunday is the 40th Annual AIDS Walk New York, which raises critical funds for GMHC and the 132,000 New Yorkers who live with HIV. CBS News New York's Vanessa Murdock introduces us to a woman who hasn't missed a single walk and says she won't stop walking until a cure is found.
HIV and AIDS memorial garden unveiled in Leicester
May 16, 2025 - By Helen McCarthy & Heather Burman - BBC - A memorial garden dedicated to those who are living with HIV or have lost their lives to AIDS has been officially opened in Leicester.
The garden, beside Holy Trinity Church in Leicester, was funded by East Midlands Sexual Health, formerly known as Leicester Aids Support Services (LASS).
Organisers said the garden honoured those who died during the early days of the HIV epidemic in the city.
Read more...
Atomic precision: Pioneering HIV vaccine triggers key immune response
May 16, 2025 - by Linda Geddes - Gavi, the Vaccine Alliance - Scientists hail a new era of HIV vaccine design, as an experimental vaccine triggers the beginnings of a broadly protective antibody response in humans.
In a step toward ending one of the world’s deadliest pandemics, researchers have shown that it’s possible to spark the beginnings of a broadly neutralising antibody response against HIV – one of vaccinology’s greatest challenges.
Two HIV vaccine trials show proof of concept for pathway to broadly neutralizing antibodies
LA JOLLA, CA and NEW YORK, NY—May 15, 2025 -IAVI and Scripps Research - A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus. Traditional approaches haven’t worked—largely because HIV mutates rapidly and hides key parts of itself from the immune system.
Now, a new study combining data from two separate phase 1 clinical trials shows that a targeted vaccine strategy can successfully activate early immune responses relevant to HIV, and, in one trial, further advance them—a key step toward a long-sought goal in vaccine development. Conducted by an international team led by scientists at IAVI and Scripps Research, the trials included nearly 80 participants from both North America and Africa, laying essential groundwork for a future HIV vaccine with global potential. The study was published in Science on May 15, 2025.
The end of bipartisan support for global AIDS treatment: 20 years of progress is on the line
May 15, 2025 - by Luke Messac - America Magazine - Two decades ago, stories like Joseph Jeune’s helped alter the course of history. In a “before” photo of him, a skeletal figure sits on a bed, eyes sunken, gaze pained. His body lacks any visible muscle or fat. He looks as he was, at death’s doorstep. In a second photo, a hale young man with a winning smile and a lithe, healthy frame holds a baby on his hip.
Health Canada approves Apretude, the first long-acting injectable for HIV prevention
May 15, 2025 - CATIE NEWS - Canadian AIDS Treatment Information Exchange (CATIE) - A long-acting formulation of cabotegravir (Apretude) has been approved for HIV prevention
This drug has been highly effective in clinical trials at significantly reducing the risk of HIV
Apretude proved superior to daily oral HIV prevention and was generally well tolerated in trials
A long-acting injectable formulation of the HIV drug cabotegravir has been developed for the prevention of HIV. In well-designed clinical trials, long-acting cabotegravir has been found to be highly effective at reducing the risk of HIV infection. Furthermore, this drug has been found to be superior to daily oral tenofovir DF + FTC (a combination sold as Truvada and available in generic formulations). One factor that may be driving this superiority is the reduced adherence requirements associated with injectable cabotegravir (an injection every two months vs. daily pill taking). The formulation of long-acting cabotegravir meant for HIV prevention is called Apretude.
 
The Global Fund to fight AIDS, Tuberculosis and Malaria should step up efforts
MAY 15 2025 - PLOS Global Public Health - PLOS Genetics - The international community must protect global responses to HIV, tuberculosis (TB), and malaria to serve humanity’s collective interests, according to an opinion article published May 14, 2025, in the open-access journal PLOS Global Public Health by Gorik Ooms from the Institute of Tropical Medicine, Belgium, and colleagues.
Within days of starting his second term as President, Donald Trump ended most United States (US) contributions to global health. Global responses to HIV, TB and malaria are not the only programs affected but were particularly dependent on US support. The US withdrawal from global health could result in 3 million additional HIV deaths and 10 million additional HIV infections, 107,000 additional malaria deaths and 15 million additional malaria infections, and 2 million additional TB deaths, all in 2025.
HIV, TB and malaria are global health security threats that require international collective action. The Global Fund to fight AIDS, TB and Malaria (Global Fund) entered its replenishment cycle for 2027–2029, with a target of $18 billion. A failure of this replenishment would make it impossible for many countries to compensate for decreasing US funding and decreasing Global Fund support.
South Africa says Trump’s aid cuts stripped more than 8,000 health workers from its HIV program
JOHANNESBURG (AP) - May 15, 2025 - By Michelle Gumede The Associated Press - TORONTO STAR - The Trump administration’s dismantling of USAID has put more than 8,000 health workers in South Africa’s national HIV program out of work, the country’s health minister said Thursday, as he outlined the impact of U.S. funding cuts on the biggest AIDS treatment project in the world.
The cuts have also closed down 12 specialized HIV clinics that were run by non-governmental organizations in South Africa and funded by the United States Agency for International Development through the U.S. President’s Emergency Plan for AIDS Relief, Health Minister Aaron Motsoaledi told reporters.
Read more...
Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution
SHELTON, CT / ACCESS Newswire / May 14, 2025 - NanoViricides, Inc. - NanoViricides Explains Its Drug Strategy for Combating Viral Infections and Pandemics
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, explains its drug development strategy to combat important global viral threats.
Measles outbreaks have continued to expand in the US, and the dramatic ten-fold increase in annual Measles cases in Europe last year indicates that Measles will be here to stay. Measles vaccine failure cases have also been increasing according to the European data, which is an important cause for concern. Vaccination rates are falling in developed countries.
In this global scenario, NV-387, the clinical stage broad-spectrum, host-mimetic antiviral nanomedicine drug could perhaps be the only currently available drug candidate to combat the Measles virus and disease. There is no approved drug for Measles virus infection.
Pair of IAVI publications demonstrate the potential value of bnAbs for HIV prevention
May 13, 2025 - IAVI - International AIDS Vaccine Initiative - Cost-effectiveness and acceptability in vulnerable populations assessed for HIV bnAbs.
Access, acceptability, and effectiveness are top of mind as scientists continue to search for new methods to address remaining gaps in HIV prevention. HIV broadly neutralizing antibodies (bnAbs) that are currently in development may present a promising future approach due to their ability to block multiple strains of HIV. They offer several other potential benefits: bnAbs are likely to be well-tolerated, will help mitigate the risk of antiretroviral resistance, and can likely induce four months of protection with just one discreet dose[1].
Two recently published papers in PLOS One assess the feasibility of HIV bnAbs in a variety of settings and populations.
Long-acting injectable HIV PrEP now available on some formularies in Canada
May 13, 2025 - CATIE NEWS - Canadian AIDS Treatment Information Exchange (CATIE) - Long-acting HIV pre-exposure prophylaxis (PrEP) is now covered by some drug plans in Canada
Cabotegravir is the first long-acting injectable form of PrEP approved by Health Canada
This highly effective option is now more accessible in Ontario, Quebec and for Indigenous people
In clinical trials, the drug cabotegravir, given as a long-acting injection ultimately every two months, is highly effective at reducing the risk for HIV infection. This liquid formulation of cabotegravir is injected deep into the buttocks by a healthcare provider. The use of cabotegravir to prevent HIV infection is called pre-exposure prophylaxis (PrEP). Cabotegravir is the first long-acting injectable for HIV prevention to be approved by Health Canada.
After a medicine is approved for use by Health Canada, a long bargaining process gets underway between Canada’s provinces and territories and the drug manufacturer, in this case ViiV Healthcare. In many cases, both sides agree on a price and the drug may then be included on the list of medicines that ministries of health are willing to subsidize. These lists are called formularies.
Secret to treating HIV came thousands of years before virus ever appeared. How?
May 13, 2025 - By Irene Wright - Miami Herald - On June 5, 1981, the Centers for Disease Control and Prevention reported five cases of an unknown infection leading to a rare kind of pneumonia.
All five men were previously young and healthy, and additional infections indicated their immune systems weren’t working. Two of them had already died.
Read more...
HIV patients in Ukraine face treatment ‘apocalypse’ as US funds in limbo
May 13, 2025 - By Lily Hyde - POLITICO - Ukraine relies on the U.S. to fund HIV services during the war. The Trump administration is still mulling axing its support.
President Donald Trump’s massive ax in January to projects funded by its international development agency USAID hit NGOs and government-run projects in Ukraine working to tackle one of the largest HIV epidemics in Europe.
Read more...
‘Loop’hole: HIV-1 Hijacks Human Immune Cells Using Circular RNAs
13 May 2025 - Newswise - Florida Atlantic University - Researchers Uncover Novel Strategy HIV-1 Uses to Evade the Immune System, Survive and Replicate
In a groundbreaking discovery, researchers from Florida Atlantic University’s Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human immunodeficiency type 1 virus (HIV-1) to evade the body’s natural defenses and use it to support its survival and replication.
The “loophole?” A biological process that involves circular RNAs (circRNAs), which form a “loop” or circle inside cells – unlike regular RNA molecules that are shaped like a straight line. This looped shape makes circRNAs much more stable and enables them to act like sponges – soaking up microRNAs (miRNAs) and preventing them from doing their usual jobs such as controlling which genes get turned on or off.
Does Discrimination Against Individuals with HIV+ Impact Pain?
May 12, 2025 - By Myles Starr - Infectious Disease Special Edition (IDSE) - More than half of all people with HIV will experience nonmalignant chronic pain throughout their lives. Recent data indicate people with HIV who experience stigma score higher on assessments of pain than those who do not (J Pain 2025 Feb:27:104746. doi: 10.1016/j.jpain.2024.104746).
Read more...
US funding cuts have crippled our HIV work – what’s being lost
May 12, 2025 - The Conversation - On his first day in office, U.S. President Donald Trump signed an executive order to freeze foreign aid funding. This was followed by a stop-work order for dozens of life-saving humanitarian programs.
One of the programs affected by this announcement is the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). This program has invested more than US$100 billion in the global HIV/AIDS response since it was founded in 2003. This makes the U.S. the largest funder of HIV/AIDS programs worldwide.
Although a 90-day waiver has since been issued which temporarily allows life-saving HIV drugs to continue being delivered, the impact of this executive order is already being felt across the globe — including in Africa, where PEPFAR funding has been integral in controlling the HIV/AIDS epidemic.
If PEPFAR funding ends when the waiver expires — or resumes but doesn’t allow funding for services to all key populations — this will have severe impacts on those in the continent living with HIV or at high-risk of infection.
The Trump Atrocity Happening in Plain Sight on the Media’s Watch
May 9, 2025 - By James North - The New Republic - The president’s demolition of the lifesaving Bush-era HIV/AIDS program will kill tens of thousands of people in sub-Saharan Africa. Why does nobody care?
A recently published study in the prestigious British medical journal The Lancet reports that the Trump administration’s evisceration of the landmark President’s Emergency Plan for AIDS Relief, or PEPFAR, program that has long been a bulwark in the fight to combat global HIV/AIDS has already sentenced tens of thousands of people in Africa to death, and with each week that passes with the program stuck in limbo, many thousands of needless deaths will follow.
Read more...
Audio documentary: A woman losing her vision to HIV/AIDS shares memories with her son
May 9, 2025 - By Noah Caldwell, Ashley Brown - NPR - Heard on All Things Considered
Producer Vivien Schütz presents the story of Gina Velasquez, who progressively lost her vision due to an HIV/AIDS diagnosis decades ago.
Listen & Read more...
When graphic design saves lives
May 9, 2025 - By Sy Boles - The Harvard Gazette - Harvard University - AIDS public health poster collection illustrates communication in a crisis
Harvard University has digitized more than 3,000 posters related to a single major public health crisis: the HIV/AIDS epidemic. The posters come from numerous countries around the world and span roughly 1990 to 2004. The collection tells a story, said Yarnell, of what the public health establishment has learned about what messages work, and why.
Read more...
Optimizing Preventive Care: A Checklist for Aging Well with HIV
May 9, 2024 - Bristish Columbia Centre for Excellence in HIV/AIDS (BC-CfE) - BC-Cfe IN-PERSON & Online LEARNING SERIES
May 21, 2025 from 12:00 – 1:00 PM (PST).
This webinar will be presented by: Melanie Murray, MD, PhD
Summarize age appropriate screening for people living and aging with HIV
Discuss cardiovascular prevention strategies
Review sex and gender specific care
The Benefits of Pharmacy Automation
May 9, 2025 - MarketsandMarkets™ - Pharmacy automation refers to the automated mechanization of pharmaceutical processes, including dispensing, sorting, packaging, labeling, storing, and retrieving medications. These systems help pharmacies streamline operations, minimize errors, and enhance patient care by automating routine and complex tasks. Thus, as the benefits of automation have grown evident, even traditional pharmacies are adopting automated solutions to improve efficiency. Pharmacy automation optimizes resource utilization and enhances accuracy by eliminating medication waste during prescription filling & labeling. Hospitals also leverage automation to improve patient outcomes and reduce long-term operational costs. Several factors, including the need to minimize medication errors, the rapid decentralization of pharmacies, the increasing elderly population, and the growing demand for automated dispensing systems, are driving market growth. According to MarketsandMarkets the pharmacy automation market is projected to reach USD 10,008.2 million by 2030 from USD 6,650.0 million in 2024, at a CAGR of 7.05% during the forecast period. This report has segmented the pharmacy automation market based on product, component, application, facility type, end user, and region.
New book explores social impacts, public health lessons from Peru’s fight against AIDS
May 8, 2025 - By Allison Arteaga Soergel - Campus News - UC Santa Cruz - Assistant Professor Justin Perez’s latest book focuses on local engagement with HIV prevention efforts in Peru during the early 2010s. During this time period, as global health leaders began to envision an “end of AIDS,” the course of the epidemic in Peru took a turn for the worse.
UC Santa Cruz scholar Justin Perez is an assistant professor of Latin American and Latino studies whose research focuses on how the ongoing global AIDS epidemic shapes the lives and social worlds of the communities most vulnerable to it. His latest book, Queer Emergent: Scandalous Stories from the Twilight of AIDS in Peru, explores the contradictions that have emerged between public health objectives and the experiences of at-risk people across Peru’s recent history.
Read more...
HIV drugs offer ‘substantial’ Alzheimer’s protection, new research indicates
8 May 2025 - University of Virginia Health System - UVA Health scientists are calling for clinical trials testing the potential of HIV drugs called NRTIs to prevent Alzheimer’s disease after discovering that patients taking the drugs are substantially less likely to develop the memory-robbing condition.
The researchers, led by UVA’s Jayakrishna Ambati, MD, previously identified a possible mechanism by which the drugs could prevent Alzheimer’s. That promising finding prompted them to analyze two of the nation’s largest health insurance databases to evaluate Alzheimer’s risk among patients prescribed the medications. In one, the risk of developing Alzheimer’s decreased 6% every year the patients were taking the drugs. In the other, the annual decrease was 13%.
High rates of HIV drug resistance among young people in London will limit future treatment options
8 May 2025 - By Keith Alcorn - aidsmap - Young people who have been living with HIV since birth have a significant unmet need for innovative long-acting treatments that can overcome drug resistance and adherence challenges, a London study has concluded. These individuals should be a priority group for inclusion in clinical trials and implementation studies of long-acting treatments, the researchers say.
The study found that over one in three young people with HIV had drug resistance patterns that could make them ineligible for injectable long-acting treatment with cabotegravir and rilpivirine.
Read more...
In Historic First, the Global Fund Procures African-Made First-Line HIV Treatment
GENEVA - 06 May 2025 - Global Fund - The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has reached a historic milestone by procuring – for the first time – a first-line HIV treatment manufactured in Africa. The treatment – lifesaving, quality-assured antiretroviral medicines (ARVs) called TLD (tenofovir, lamivudine and dolutegravir), prequalified by the World Health Organization – was sourced from a leading Kenyan pharmaceutical company and delivered to Mozambique. The volume supplied can treat over 72,000 people per year in the country.
Scottish Government announces roll-out of opt-out HIV and hepatitis testing in A&Es
6 May 2025 - Terrence Higgins Trust - In a boost to Scotland’s efforts to end new HIV cases by 2030, a game-changing approach to blood-borne virus testing will be rolled-out in Edinburgh and Glasgow thanks to new Scottish Government funding.
The Scottish Government has today [6 May 2025] announced new funding for the roll-out of opt-out blood borne virus testing in emergency departments in cities with a high HIV prevalence. The decision follows three pilots of opt-out testing in NHS Lothian, NHS Grampian and NHS Highland in 2024 and a sustained campaign from Terrence Higgins Trust and partners across Scotland’s HIV sector, backed by our supporters in parliament and beyond.
AI plays detective to help scientists find hidden microbes
May 5, 2025 - By Bernard Rizk - University of Ottawa - New machine learning tool redefines microbial rare biosphere
A team of researchers has created a novel machine learning tool that's cracking open one of biology's trickiest puzzles: finding the rarest microbes on Earth. Think of it like finding a needle in a haystack, except the needle is microscopic and might hold the key to how our ecosystems work.
The tool, called ulrb, uses AI to spot these elusive microorganisms that, despite their tiny numbers, pack a serious punch in keeping our planet's ecosystems healthy. It's like having a super-smart detective that can pick out the rare gems from billions of othermicrobes.
Older adults are getting infected with HIV, but prevention focuses on young people
May 5, 2025 - Wits University - Prevention and treatment campaigns are not adequately targeting the particular needs of the 50+ years age group.
Indeed, between 2000 and 2016, the number of adults aged 50 years and older living with HIV in sub-Saharan Africa doubled. At present, their HIV prevalence is exceeding that of younger adults.
By 2040, one-quarter of people living with HIV in Africa will be aged 50 years and older; tailored awareness and treatment campaigns are pressing.
Dr Luicer Olubayo, a researcher at the Sydney Brenner Institute for Molecular Bioscience (SBIMB) at Wits University and the first author of a study published in The Lancet Healthy Longevity journal, which investigated HIV in older people in Kenya and South Africa, noted that perceptions on who acquires HIV are limited. “We often think of HIV as a disease of younger people. It doesn’t help that intervention campaigns are mainly targeted at the youth.”
Guidance Offers Recommendations For Expanding Care to Homeless People With HIV
May 5, 2025 - By Aaron Tallent - Infectious Disease Special Edition (IDSE) - A number of programs across the country are designed to reach and provide healthcare to people experiencing homelessness, including those who are living with HIV. However, these initiatives also face challenges in finding adequate funding. To help meet their needs, the HIV Medicine Association (HIVMA) and Center for Health Care Strategies have issued guidance to help providers develop and sustainably fund low-barrier clinics and street medicine
Read more...
ICE Detainee Dies After HIV Undiagnosed for Months During Custody
May 02, 2025 - By Billal Rahman - Newsweek - Nanette Kazaoka, a well-known figure in the fight for HIV/AIDS awareness and the rights of marginalized communities, passed away on Oct. 2 at her home on the Upper West Side. She was 83. Her daughter, Kelly Kochendorfer, confirmed that the cause of death was complications from vascular dementia and Alzheimer’s disease.
The 45-year-old Ethiopian man died on January 29, 2025, from “Complications of multiple infections in the setting of human immunodeficiency virus,” according to a medical examiner's report filed two days later.
Read more...
HIV care quality has been improving for older adults
May 1, 2025 - By Maya Brownstein -Harvard T.H. Chan School of Public Health - More people living with HIV and enrolled in Medicare are taking modern, less toxic antiretroviral drugs than ever before, according to a new study led by Harvard T.H. Chan School of Public Health. The findings signal positive progress in care for people living with HIV, particularly older adults who now make up most of the HIV-positive population in the U.S. Researchers warn, however, that this progress may be upended by recent federal funding cuts to HIV prevention and care programs.
The study was published May 1 in JAMA Network Open. Jose Figueroa, associate professor of health policy and management, was corresponding author. Other co-authors included staff of the Healthcare Quality and Outcomes Lab: Dannie Dai, research assistant and statistical programmer; Ciara Duggan, research assistant; and Jessica Phelan, assistant director of analytics.
Nanette Kazaoka, an unlikely AIDS activist, dies at 83
May 1, 2025 - By Kelly Kochendorfer - Gay City News- A man who died in ICE custody earlier this year from complications related to untreated HIV could have been saved with the help of routine blood tests, medical experts have told Newsweek, raising concerns about health screening in detention facilities.
Kazaoka was a fearless advocate for justice, particularly in the early days of the AIDS crisis, when she became a member of the AIDS Coalition to Unleash Power, or ACT UP. She is perhaps best remembered for her participation in a 2004 protest in front of Madison Square Garden during the Republican National Convention, when she and 11 fellow activists staged a dramatic naked demonstration demanding debt cancellation for impoverished countries. “Bush, Stop AIDS. Drop the Debt Now!” they chanted, with slogans stenciled in black paint on their bodies. The bold protest drew national attention and underscored the urgency of global debt relief as a key element in the fight against AIDS.
Read more...
Males are more likely to get sick and less likely to seek care for three common diseases
May 1, 2025 - PLOS Medicine - A global analysis finds sex-based health disparities for hypertension, diabetes and HIV and AIDS
In many countries, males are more likely than females to get sick and die from three common conditions, and less likely to get medical care, according to a new study by Angela Chang of the University of Southern Denmark, and colleagues, published May 1st in the open-access journal PLOS Medicine.
Many health policies are the same for males and females, even though there is strong evidence that sex and gender can substantially influence a person’s health outcomes. In the new study, researchers gathered global health data for people of different sexes and ages for three conditions, hypertension, diabetes, and HIV and AIDS. By comparing rates of diseases between males and females and differences in diagnosis and treatment, the researchers sought to illuminate and reduce health inequities between the sexes.
Two Chicago HIV Groups Mark Milestones While Raising Funds
May 1, 2025 - By Laura Schmidt - POZ - Howard Brown Health and the AIDS Foundation of Chicago hosted galas to celebrate decades of providing lifesaving health services.
Last month, two Chicago-based HIV service organizations, Howard Brown Health and AIDS Foundation Chicago, marked major milestones with festive fundraiser galas.
To celebrate 50 years of lifesaving work, Howard Brown, one of the nation’s largest LGBTQ organizations, hosted an anniversary gala on April 26 at Chicago’s Theater on the Lake.
Read more...
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS: HIV/AIDS News Archive
Back to Top
HIV/AIDS News
|
